iCAD, Inc. (ICAD)

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of iCAD, Inc. (NasdaqCM: ICAD) to RadNet, Inc. (NasdaqGM: RDNT). Under the terms of the proposed transaction, shareholders of iCAD will receive 0.0677 shares of RadNet for each share of iCAD that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequat.

NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of iCAD, Inc. (NasdaqCM: ICAD) to RadNet, Inc. (NasdaqGM: RDNT). Under the terms of the proposed transaction, shareholders of iCAD will receive 0.0677 shares of RadNet for each share of iCAD that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequat.

NEW YORK , April 16, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating iCAD, Inc. (NASDAQ: ICAD ), relating to the proposed merger with RadNet, Inc. Under the terms of the agreement, iCAD stockholders will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock held at the closing of the merger.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of iCAD, Inc. (NASDAQ: ICAD) to RadNet, Inc. for 0.0677 shares of RadNet common stock for each share of iCAD common stock is fair to iCAD shareholders. Halper Sadeh encourages iCAD shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation c.

NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD.

iCAD, Inc. (NASDAQ:ICAD ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants Rosalyn Christian - IR Dana Brown - President, CEO and Chairman Eric Lonnqvist - CFO Conference Call Participants Marie Thibault - BTIG Per Ostlund - Craig-Hallam Capital Yale Jen - Laidlaw & Company Gene Mannheimer - Freedom Capital Markets Operator Greetings. Welcome to the iCAD Inc. Fourth Quarter and Full Year 2024 Financial Results Conference Call.

NASHUA, N.H., March 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024.

NASHUA, N.H. and TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and RamSoft®, a global leader in cloud-based RIS/PACS radiology solutions for imaging centers and providers, today announced a new strategic commercial preferred distributor and integration partnership across the US and Canada. With over 750 sites and thousands of healthcare providers worldwide utilizing RamSoft's solutions, this collaboration brings iCAD's ProFound AI® Breast Health Suite directly into imaging centers, enhancing workflow efficiency, increasing diagnostic confidence, and improving patient care, beginning within the platforms they already use.

NASHUA, N.H. and CHICAGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and Koios Medical, a leader in AI-driven ultrasound cancer diagnosis, today announced a strategic reseller partnership to deliver a comprehensive, multi-modality AI suite for breast cancer detection. This collaboration integrates iCAD's ProFound AI® Breast Health Suite for mammography with Koios SmartUltrasound™, providing radiologists with an AI-powered pathway from screening to diagnosis.

NASHUA, N.H., Feb. 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced that five clinical presentations and abstracts highlighting the Company's advancements in breast cancer detection, risk evaluation, and breast arterial calcification (BAC) assessment have been accepted for presentation at the European Congress of Radiology (ECR) 2025, which will take place from February 26 to March 2, 2025, in Vienna, Austria.

iCAD to Participate in the BTIG at Snowbird: 12 th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

-New FDA Consultant is the former Director of the Division of Imaging, Diagnostics, and Software Reliability at the U.S Food and Drug Administration- -New Biostatistical Consultant is the former Deputy Director of the Biostatistics and Data Management Center of the American College of Radiology Imaging Network, an NIH-funded cooperative that conducts clinical trials to evaluate the use of diagnostic imaging and image-guided treatments for cancer, has decades of successful experience in design and analysis of clinical studies of medical imaging devices supporting U.S. Food and Drug Administration approval applications - -New Regulatory Consultant is the former VP of Regulatory Affairs, Clinical Affairs, and Quality Assurance for iCAD (NASDAQ: ICAD), a medical device manufacturer that offers computer-aided detection solutions for cancers including breast, and technology platforms including hardware and software for radiation therapy treatment- Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - January 15, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce that Dr. Kyle J. Myers, Dr. Alicia Toledano, and Mr.

Reveals Higher Prevalence of Breast Arterial Calcifications (BAC) in Breast Cancer Patients, Suggesting Potential Need for Cardiovascular Assessment Alongside Oncological Treatment Reveals Higher Prevalence of Breast Arterial Calcifications (BAC) in Breast Cancer Patients, Suggesting Potential Need for Cardiovascular Assessment Alongside Oncological Treatment

ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025

ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025